MiR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hennino, Marie Flore ^a,b   Buob, David ^c   Van Der Hauwaert, Cynthia ^a   Gnemmi, Viviane ^d   Jomaa, Zacharie ^e   Pottier, Nicolas ^a   Savary, Grégoire ^a   Drumez, Elodie ^f   Noël, Christian ^d   Cauffiez, Christelle ^a   Glowacki, François ^a  

^a UFR3S Pharmacie   (France)

^b CENTRE HOSPITALIER DE VALENCIENNES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIV LILLE   (France)

^e Centre Hospitalier de Cambrai   (France)

^f UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN21 MICRORNA, HUMAN;

ADULT; FEMALE; FIBROSIS; GENETICS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY; MALE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; UPREGULATION; YOUNG ADULT;

ADULT; FEMALE; FIBROSIS; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; MALE; MICRORNAS; MIDDLE AGED; RISK FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 84973277678     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27209     Document Type: Article

References (39)

1. Schena, F. P. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am. J. Med. 89, 209-215 (1990).
2. Xie, J. et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One 7, e38904 (2012).
3. Kiryluk, K. et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat. Genet. 46, 1187-96 (2014).
4. Moldoveanu, Z. et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 71, 1148-54 (2007).
5. Suzuki, H. et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119, 1668-77 (2009).
6. Moura, I. C. et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J. Am. Soc. Nephrol. 16, 2667-76 (2005).
7. Magistroni, R., D'Agati, V. D., Appel, G. B. & Kiryluk, K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 88, 974-89 (2015).
8. Wyatt, R. J. & Julian, B. A. IgA nephropathy. N. Engl. J. Med. 368, 2402-14 (2013).
9. Farris, A. B. & Colvin, R. B. Renal interstitial fibrosis: mechanisms and evaluation. Curr. Opin. Nephrol. Hypertens. 21, 289-300 (2012).
10. Roberts, I. S. et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 76, 546-556 (2009).
11. Cattran, D. C. et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76, 534-545 (2009).
12. Coppo, R. et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 86, 828-836 (2014).
13. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105 (2009).
14. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874 (2011).
15. Szeto, C. C. & Li, P. K. MicroRNAs in IgA nephropathy. Nat. Rev. Nephrol. 10, 249-56 (2014).
16. Glowacki, F. et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoSOne 8, e58014 (2013).
17. Lino Cardenas, C. L. et al. MiR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 9, e1003291 (2013).
18. Savary, G. et al. MiR-214-3p, a new fibromiR involved in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. J. 44 (2014).
19. Pottier, N., Cauffiez, C., Perrais, M., Barbry, P. & Mari, B. FibromiRs: translating molecular discoveries into new anti-fibrotic drugs. Trends Pharmacol. Sci. 35, 119-26 (2014).
20. Zarjou, A., Yang, S., Abraham, E., Agarwal, A. & Liu, G. Identification of a microRNA signature in renal fibrosis: Role of miR-21. Am. J. Physiol. Renal Physiol. 301, F793-F801 (2011).
21. Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra18 (2012).
22. Dweep, H., Sticht, C., Kharkar, A., Pandey, P. & Gretz N. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model. PLoS One 8, e53780 (2013).
23. Denby, L. et al. MicroRNA-214 antagonism protects against renal fibrosis. J. Am. Soc. Nephrol. 25, 65-80 (2014).
24. Van Rooij, E., Purcell, A. L. & Levin, A. A. Developing MicroRNA Therapeutics. Circ. Res. 110, 496-507 (2012).
25. Serino, G., Sallustio, F., Cox, S. N., Pesce, F. & Schena, F. P. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J. Am. Soc. Nephrol. 23, 814-24 (2012).
26. Serino, G. et al. Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy. Nephrol. Dial. Transplant. 30, 1132-9 (2015).
27. Wang, G. et al. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab. Invest. 90, 98-103 (2010).
28. Wang, G. et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers 30, 171-9 (2011).
29. Wang, G. et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers 28, 79-86 (2010).
30. Wang, G. et al. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am. J. Nephrol. 36, 412-8 (2012).
31. Bao, H. et al. Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. Biochem. Biophys. Res. Commun. 444, 455-60 (2014).
32. McClelland, A. D. et al. MiR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin. Sci. (Lond.) 129, 1237-49 (2015).
33. Fang, Y. et al. MiR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation. Am. J. Physiol. Renal Physiol. 304, F1274-82 (2013).
34. Szeto, C. C. et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers 33, 137-44 (2012).
35. Gomez, I. G. et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 125, 141-56 (2015).
36. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta DeltaC(T)) Method. Methods 25, 402-8 (2001).
37. Schoenfeld, D. Partial residuals for the proportional hazards regression model. Biometrika 69, 239-241 (1982).
38. Lin, D. Y., Wei, L. J. & Ying, Z. Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Biometrika 80, 557-572 (1993).
39. Contal, C. & O'Quigley, J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput. Stat. Data Anal. 30, 253-270 (1999).